Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) was the recipient of unusually large options trading on Wednesday. Investors acquired 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the average volume of 165 put options.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 65,302 shares of company stock valued at $2,924,128. 4.07% of the stock is owned by insiders.

Institutional Trading of Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC purchased a new position in Xenon Pharmaceuticals in the second quarter worth $25,000. Elevation Point Wealth Partners LLC purchased a new stake in Xenon Pharmaceuticals during the second quarter valued at about $32,000. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals during the 3rd quarter valued at about $32,000. Blue Trust Inc. lifted its position in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in Xenon Pharmaceuticals in the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Down 1.2%

NASDAQ:XENE opened at $41.00 on Thursday. The stock has a market cap of $3.17 billion, a P/E ratio of -10.54 and a beta of 0.97. The business’s 50-day moving average price is $42.86 and its two-hundred day moving average price is $39.13. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.60.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.01. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.81) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on XENE shares. Chardan Capital raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Royal Bank Of Canada increased their price objective on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Wells Fargo & Company increased their price target on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, December 11th. Finally, William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $54.82.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.